Core Insights - The 2026 Nuclear Fusion Energy Technology and Industry Conference was held in Hefei, showcasing commercializable technologies derived from nuclear fusion research, which has garnered significant attention in the industry [1][3] Group 1: Technological Developments - Nuclear fusion energy simulates the fusion reactions of the sun, releasing energy and is regarded as humanity's "ultimate energy" [1] - Superconducting technology used for plasma confinement has been applied to develop more efficient medical magnetic resonance devices [1] - Technologies developed for creating extreme vacuum environments are aiding in the upgrade of semiconductor manufacturing equipment [1] - New materials that can withstand extreme conditions are finding applications in aerospace and other fields [1] Group 2: Industry Ecosystem - Hefei has established a complete innovation ecosystem with major scientific infrastructures, including the EAST, BEST, and CRAFT, and has gathered over 60 companies related to the nuclear fusion industry chain [3] - The local government and research institutions have identified dozens of fusion-derived technologies with commercialization potential and have created a project database for precise matching [3][5] - Companies are collaborating with research units to establish joint laboratories, facilitating early involvement in R&D and rapid application of results to high-end industrial uses [3] Group 3: Financial Initiatives - The "Fusion Financial Institutions Alliance" was established to provide services covering the entire lifecycle of fusion technology [4] - The Hefei Future Fusion Energy Venture Capital Fund was launched, targeting long-term capital for key technologies and core aspects of fusion energy [4] Group 4: Policy Support - During the 14th Five-Year Plan period, Anhui Province has created a list of derived technologies from large scientific devices to support secondary development and establish a comprehensive application system [5] - The province has incubated and introduced over 100 technology-based enterprises in fields such as superconducting materials, plasma diagnostics, low-temperature technology, and terahertz lasers [5]

Group 1 - The European Commission has imposed a ban on Chinese medical device companies from participating in public tenders exceeding €5 million (approximately ¥40 million), which is expected to reshape the global medical device industry landscape [2][3] - The ban is part of a broader trade conflict centered around "fair competition," with the EU's investigation into China's procurement practices highlighting the requirement for a certain level of domestic production [3][4] - China's Ministry of Finance responded with a countermeasure, excluding EU companies from government procurement projects valued over ¥4.5 million, specifically targeting 50 types of medical devices imported from the EU [5][6] Group 2 - Despite the challenges posed by the EU's procurement barriers, the Chinese medical device industry still sees potential in overseas markets, particularly in regions with unmet medical needs such as Asia, Africa, and Latin America [6][7] - Companies are encouraged to adapt their strategies by collaborating with local firms and establishing overseas production bases to navigate trade barriers and maintain market presence [6][7] - The global medical device supply chain is undergoing rapid restructuring, indicating a shift in competitive dynamics as new markets emerge [7]